SINO BIOPHARM (01177) has announced the completion of its share acquisition deal for 100% of the equity in Hejiya, which involved issuing consideration shares under a general mandate. The board confirmed that all conditions precedent under the sale and purchase agreement have been fulfilled, with the transaction settled on March 30, 2026. Following the completion, Hejiya has become an indirect wholly-owned subsidiary of the company, and its financial results will be consolidated into the group's financial statements.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments